On September 18, 2025, IceCure Medical Ltd. announced it received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent titled 'Cryoprobe.' This invention is designed to improve cryoprobe extraction, further reducing the risk of tissue trauma, which can lead to lower costs and an improved patient experience. The new cryoprobe technology is integrated into IceCure's next-generation XSense™ system.
The invention introduces a novel method for safely and efficiently extracting the cryoprobe after tissue freezing during cryoablation procedures. It incorporates a heater, temperature sensor, and controlled gas pulses at the cryoprobe's tip, enabling precise estimation and management of the external surface temperature while embedded in frozen tissue. This technology is compatible with a wide range of XSense™ system cryoprobe types, offering a versatile solution for multiple clinical scenarios.
IceCure's CEO, Eyal Shamir, stated that this advancement further enhances the company's industry-leading liquid nitrogen-based cryoablation platform. The XSense™ system with these cryoprobes recently received regulatory approval in both the U.S. and Israel, positioning IceCure to deliver improved patient outcomes and experiences with its minimally invasive outpatient procedures.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.